Alios Biopharma, Inc.

Vertex Pharmaceuticals, Inc.

David Richard Willcox

Ales Medek

Michael Waldo

Young Chun Jung

Lori Ann Ferris

Praveen Mudunuri

William Aloysius Nugent

Anuj K Kuldipkumar

The present application relates to solid state forms, for example, crystalline forms of 2'-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.

Solid forms of a thiophosphoramidate nucleotide prodrug

The present application relates to solid state forms, for example, crystalline forms of 2'-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.

Growing community of inventors

Wellesley, MA, United States of America

David Richard Willcox